Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlo Pozzilli

Showing results (231-240 of 247) with videos related to

Pageof 25
Sort By:
Therapeutic Advances in Neurological Disorders|December 31, 2025
Real-world experience with cladribine tablets in people with multiple sclerosis: effectiveness data from a multicenter Italian studyMatteo Lucchini, Giovanna Borriello, Shalom Haggiag, et al.
The Lancet. Neurology|July 23, 2011
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoringLudwig Kappos, David Bates, Gilles Edan, et al.
Therapeutic Advances in Neurological Disorders|June 9, 2021
Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategiesPietro Iaffaldano, Giuseppe Lucisano, Francesca Caputo, et al.
Brain : a Journal of Neurology|September 13, 2015
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosisPietro Iaffaldano, Giuseppe Lucisano, Carlo Pozzilli, et al.
Neurology|November 24, 2025
Disability Worsening Phenotypes in Multiple Sclerosis and Impact of Disease-Modifying TreatmentsErmelinda De Meo, Ilaria Addazio, Emilio Portaccio, et al.
Neurology|September 22, 2025
Toward a Unified Definition of Progression Independent of Relapse Activity in Multiple SclerosisEmilio Portaccio, Matteo Betti, Ermelinda De Meo, et al.
JAMA Neurology|July 25, 2022
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple SclerosisEmilio Portaccio, Mattia Fonderico, Pietro Iaffaldano, et al.
Journal of Neurology|September 20, 2019
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS RegisterDamiano Paolicelli, Giuseppe Lucisano, Alessia Manni, et al.
Brain : a Journal of Neurology|September 16, 2020
Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosisMaria Pia Amato, Mattia Fonderico, Emilio Portaccio, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 16, 2022
Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS RegisterPietro Iaffaldano, Giuseppe Lucisano, Tommaso Guerra, et al.
Pageof 25

Showing results (231-240 of 247) with videos related to

Sort By:
Pageof 25
Therapeutic Advances in Neurological Disorders|December 31, 2025
Real-world experience with cladribine tablets in people with multiple sclerosis: effectiveness data from a multicenter Italian studyMatteo Lucchini, Giovanna Borriello, Shalom Haggiag, et al.
The Lancet. Neurology|July 23, 2011
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoringLudwig Kappos, David Bates, Gilles Edan, et al.
Therapeutic Advances in Neurological Disorders|June 9, 2021
Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategiesPietro Iaffaldano, Giuseppe Lucisano, Francesca Caputo, et al.
Brain : a Journal of Neurology|September 13, 2015
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosisPietro Iaffaldano, Giuseppe Lucisano, Carlo Pozzilli, et al.
Neurology|November 24, 2025
Disability Worsening Phenotypes in Multiple Sclerosis and Impact of Disease-Modifying TreatmentsErmelinda De Meo, Ilaria Addazio, Emilio Portaccio, et al.
Neurology|September 22, 2025
Toward a Unified Definition of Progression Independent of Relapse Activity in Multiple SclerosisEmilio Portaccio, Matteo Betti, Ermelinda De Meo, et al.
JAMA Neurology|July 25, 2022
Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple SclerosisEmilio Portaccio, Mattia Fonderico, Pietro Iaffaldano, et al.
Journal of Neurology|September 20, 2019
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS RegisterDamiano Paolicelli, Giuseppe Lucisano, Alessia Manni, et al.
Brain : a Journal of Neurology|September 16, 2020
Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosisMaria Pia Amato, Mattia Fonderico, Emilio Portaccio, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 16, 2022
Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS RegisterPietro Iaffaldano, Giuseppe Lucisano, Tommaso Guerra, et al.
Pageof 25